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fever. She had lower abdominal pain and bloating for the last 2 months
with decreased appetite, nausea, and a 22-pound weight loss.
On examination, the patient had a palpable abdominal mass with
diffuse rebound tenderness and rigidity. Computed tomography (CT)
scan showed a complex pelvic mass measuring 19.8×17.8×14.5 cm
invading and perforating the sigmoid colon (Fig. 1).
Exploratory laparotomy showed infected ascites from a sigmoid
colon perforation. This mass also extended to the right ovary and in-
vaded the terminal ileum and the cecum. Optimal debulking to no vis-IntroductionAngiosarcomas are rare, accounting for 2% of soft tissue sarcomas,
with only a fraction of these cases being located in the ovary (Penel et
al., 2008). Exceedingly rare is a malignant transformation of a mature
cystic teratoma into an angiosarcoma.
Mature cystic teratomas are the most common type of ovarian neo-
plasm and are usually benign (Koonings et al., 1989). Rarely (0.8–2%) a
mature cystic teratoma undergoes malignant transformation of which
squamous cell is the most common histology (Koonings et al., 1989;
Contreras and Malpica, 2009). The clinical prognosis, and hence the ad-
juvant therapy, of a patient with such transformation depends on the
histology of the transformed cells rather than the teratoma itself (den
Bakker et al., 2006).
There have been only 5 reported cases in English literature to date
of a mature cystic teratoma with transformation to angiosarcoma.
Angiosarcomas have aggressive clinical behavior with poor patient
prognoses. This case is the 6th report of this disease. We also review
the current adjuvant treatment strategies.
Case
A 64 year-old female with a history of type 2 diabetes mellitus, hy-
pertension, and vaginal hysterectomy for uterine leiomyomas 30 yearspitals and Clinics, 600 Highland
Inc. Open access under CC BY-NC-SA licenseible disease was performed with bilateral salpingo-oophorectomy,
resection of the terminal ileum and cecum with side-to-side anasto-
mosis, resection of sigmoid and upper rectum, and a formation of a
permanent descending end colostomy. The patient was discharged
home after four days of inpatient hospitalization.
Pathologic evaluation of themass showed angiosarcoma involving bi-
lateral ovarieswith extensive necrosis associatedwith the cystic teratoma
of the left ovary (Fig. 2). Microscopic examination revealed atypical cells,
varying from spindled to an epithelioid character with abundant cyto-
plasm, and large hyperchromatic, pleomorphic nuclei. The tumor showed
solid, sheet-like areas and vascular spaces. Immunohistochemisty of the
tumor showed intense staining for CD31 and vimentin, reacted weakly
for FLI-1, but had lost expression of CD34 and factor VIII related antigen.
Additional staining for CD117, DOG-1, S100, desmin, muscle-speciﬁc
actin, myogenin, melanoma cocktail, and cytokeratin AE1/AE3 were neg-
ative. The tumor additionally involved the left peri-fallopian soft tissue,
pelvic soft tissue, and right peri-adnexal tissue. Metastatic foci involved
full thickness of the sigmoid colon wall, terminal ileum, and one regional
lymph node.
After extensive counseling and given the extent of the disease, thede-
cisionwasmade to start adjuvant chemotherapy to be followed by radio-
therapy (RT). Three weeks after recovering from her surgery, the patient
received intravenous paclitaxel (175 mg/m2=362 mg) to be scheduled
every 3 weeks. More studies have looked in to the use of paclitaxel as a
single agent in sarcoma literature rather than combination chemothera-
py. Considering this and the patient's medical co-morbidities and
performance status, single agent paclitaxel was used as an adjuvant
treatment. However, she was readmitted 2 weeks later with a recur-
rence of her original symptoms and CT scan showing recurrence of
her cancer to the pelvis and upper abdomen. With a rapid clinical dete-
rioration, the patient developedmulti-organ failure and elected to be at
homewith hospice care. She passed away 2 weeks later—8 weeks after
initial diagnosis and 4 months after her symptoms began..
Fig. 1. Angiosarcoma CT.
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Mature cystic teratomas are relatively common ovarian neo-
plasms (Koonings et al., 1989). Rarely, malignant transformation of
a mature cystic teratoma can occur (Koonings et al., 1989). These
malignancies are typically squamous cell carcinomas, and only a
few cases have been reported of transformation of a mature cystic
teratoma into an angiosarcoma (Contreras and Malpica, 2009). The
overall survival of those patients with mature cystic teratoma trans-
formation to angiosarcoma varies from 2 to 29 months (Contreras
and Malpica, 2009; den Bakker et al., 2006; Nielsen et al., 1997;
Devouassoux-Shisheboran et al., 2000). It is difﬁcult to study the opti-
mal adjuvant therapy, because of the paucity of cases and their aggres-
sive clinical behavior. No study has focused solely on the treatment of
ovarian angiosarcomas.
Adjuvant treatment of angiosarcomas in general varies according to
the anatomic location of primary tumor site. Those originating above
the clavicle have better prognosis than those originating below it
(Penel et al., 2008).
In head and neck (mainly scalp) angiosarcomas, surgical excision
should be followed by radiotherapy if the surgical margins are posi-
tive. In patients with negative surgical margins, radiotherapy isFig. 2. Cyst wall with adjacent angiosarcoma; H&E.optional. Intra-abdominal angiosarcomas are most likely metastatic
and hence necessitate surgical excision with adjuvant chemotherapy,
which can be in the form of intra-operative radiotherapy (IORT), or
post-operative radiotherapy (RT), or chemotherapy.
Post-treatment surveillance with CT can be done every 3–6 months
for 2–3 years.
English literature review revealed only ﬁve cases of angiosarcoma
derived from mature cystic teratoma. Three of these case reports fo-
cused on the pathologic diagnosis of angiosarcomas frommature cys-
tic teratomas (Contreras and Malpica, 2009; den Bakker et al., 2006;
Nielsen et al., 1997). Another report evaluated the genotypes of the
malignant components of mature teratomas in a patient with two
separate malignant teratomas that transformed into angiosarcomas
with independent genetic origin (Devouassoux-Shisheboran et al.,
2000). These cases, in addition to the current case, are summarized
in Table 1.
Doxorubicin-based chemotherapy was considered the standard-of-
care treatment in metastatic soft tissue sarcomas (Penel et al.,
2008). However, recent literature suggests that paclitaxel, docetaxel,
vinorelbine, sorafenib, sunitinib, and bevacizumab can be considered
for angiosarcomas as a single or multiple agent therapy.
The ANGIOTAX phase II trial suggested the utility of paclitaxel in ad-
vanced angiosarcomas (Penel et al., 2008). At low concentrations of con-
tinuous infusion, paclitaxel has potent anti-angiogenic effects, but ismore
active against angiosarcomas above the clavicle (Penel et al., 2008). One
retrospective studyhas suggested that the efﬁcacy of paclitaxelmaydiffer
depending on the location of the angiosarcoma in the body (Fury et al.,
2005). Paclitaxel was more effective when the angiosarcoma was above
the clavicle, with a progression free survival of 6.8±4.3 months. Non-
paclitaxel regimens used for treating unresectable angiosarcomas below
the clavicle provided a progression free survival of 3.7±0.9 months
while paclitaxel provided 2.8±0.2 months progression free survival for
these patients (Fury et al., 2005). However, paclitaxel is the most
commonly used therapy for angiosarcomas and there is a paucity of ran-
domized trials evaluating the efﬁcacy of paclitaxel below the clavicle
(Fury et al., 2005).
As more knowledge is gained about biologic markers that are
associated with angiosarcomas, therapies can be developed to target
these growth factors and receptors. VEGF and KDR (VEGF-R2) are
believed to play a role in angiosarcoma growth and may be potential
targets for future therapies (Ray-Coquard et al., 2012). A phase II
study assessed sorafenib (inhibitor of several tyrosine protein
kinases, including VEGF and Raf kinases) in patients with recurrent
or metastatic sarcomas showed a progression free survival rate of
3.8 months (Ray-Coquard et al., 2012). However, this study also
showed that standard cytotoxic treatments continue to have better
response rates (Ray-Coquard et al., 2012). Another phase II trial by
the French Sarcoma Group suggested that sorafenib had very limited
anti-tumor activity in patients that had been pre-treated with anoth-
er chemotherapy and had no utility in patients who had not been
pre-treated (Ray-Coquard et al., 2012). Sorafenib may be useful in
the therapy in the future, as in vitro studies have shown high sensitiv-
ity to angiosarcomas with an activating mutation in the KDR protein
(Ray-Coquard et al., 2012).
Angiosarcoma of the ovary is a rare but aggressive disease.
Current literature suggests management with chemotherapy, ra-
diation therapy, palliative surgery, or supportive care for recurrent
unresectable disease. Paclitaxel may provide some additional survival
beneﬁt in addition to standard therapy. The aggressive nature of
intra-abdominal angiosarcomas warrants further research on newer
anti-angiogenic chemotherapies that may provide longer progression-
free survival.
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Table 1
Summary of previous case reports on cystic teratomas with transformation to angiosarcoma.
Case report Number
of cases
Age of patient
(years)
Stage of cancer Surgery Therapy Time from diagnosis to
death (months)
Neilsen (6) 2 20–32
(average 26)
III Not available Not available 2, 15, 30 (average 15.7)
Devouassoux-Shisheboran (3) 1 40 IV Not available Not available Not available
den Bakker (2) 1 30 Probable IIIC Exploratory laparotomy, left oophorectomy
and removal of cystic tumor, staging and
subtotal omentectomy.
Recurrence at 5 months: debulking,
hysterectomy, right oophorectomy and
removal of residual omentum.
3 cycles of BEP (bleomycin,
etoposide and cisplatin);
1 course of EP
9
Contreras (1) 1 32 Not available Total hysterectomy, bilateral
salpingo-oophorectomy, tumor debulking,
omentectomy, and appendectomy.
5 cycles of high-dose
ifosfamide+1 doxorubicin;
29
Albertin (current case) 1 64 IIIC Exploratory laparotomy, debulking, bilateral
salpingo-oophorectomy, resection of the
terminal ileum and cecum with side-to-side
anastomosis, resection of sigmoid and upper
rectum, and formation of a permanent
descending end colostomy.
1 cycle of paclitaxel 1.5
33C. Albertin et al. / Gynecologic Oncology Reports 5 (2013) 31–33beginning the submitted work that could inappropriately inﬂuence, or be perceived to
inﬂuence, their work.
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